Table 2 Base-case analysis results for cost-effectiveness of pralatrexate versus conventional chemotherapy in treating R/R PTCL1
Pralatrexate | Conventional chemotherapy | Incremental value (pralatrexate vs. coven. Chemo.) | |
|---|---|---|---|
Total costs ($) | 48,677 | 20,045 | 28,632 |
Initial treatment cost | 32,804 | 2504 | 30,301 |
Concomitant drug cost (initial tx.) | 45 | 2167 | -2122 |
Subsequent treatment cost | 1842 | 810 | 1033 |
Concomitant drug cost (subseq. tx.) | 1533 | 674 | 860 |
Monitoring test cost (initial tx.) | 273 | 461 | − 188 |
Monitoring test cost (subseq. tx) | 322 | 143 | 179 |
Cost to treat AE | 7170 | 10,554 | − 3383 |
SCT cost | 4686 | 2733 | 1953 |
Life years (LYs) | 3.499 | 1.932 | 1.567 |
Quality-adjusted life years (QALYs) | 1.075 | 0.344 | 0.731 |
Incremental cost per LY gained | – | – | 18,276 |
Incremental cost per QALY gained | – | – | 39,153 |